Our laboratory study the architecture of the human interactome during the establishment of diseases such as diabetes, alzheimer's disease, als and certain leukodystrophies in order to better understand the causative mechanisms and develop cures

Notre laboratoire étudie l'architecture de l'interactome humain lors de l'établissement de maladies comme le diabète, la maladie d'alzheimer, la sla et certaines leucodystrophies afin de mieux comprendre les mécanismes causatifs et développer des remèdes

Interception Medicine based on Proteome Profiling and Reprogramming

Towards an Interception Medicine Clinic

I lead a remarkable research team that develops "interception medicine", a new approach that aims for the ultra-early detection and correction of molecular disturbances in cells when the phenotypic trajectory shift towards disease conditions. Since proteins are the functional actors of our cells, their role in diseases is direct and their profiling is very informative.

With Dr. Geneviève Bernard (McGill University Health Centre, MUHC) and a few other colleagues, and thanks to sustained funding from the Canadian Institutes of Health Research and the Leukodystrophy Foundation (Quebec), we discovered that, for example, genetic variations affecting subunits of RNA polymerase III, an enzyme central to the gene expression process, disrupt the assembly of this enzyme and cause ​a brain white matter disorder called leukodystrophy.

We have also found that certain defects in RNA polymerase III assembly can be at least partially reversed by treating cells with Riluzole, a compound already approved by the US FDA for amyotrophic lateral sclerosis (ALS). The effect of Riluzole in organisms with leukodystrophy-related disorders and its mechanism of action are currently being investigated in our laboratory. Aiming for the cause of the disease as a therapeutic target, i.e. the assembly of RNA polymerase III in this case, rather than its consequence, i.e. the defect in myelination that occurs months or years later, appears as a promising strategy to discover cures.

We also believe that massive profiling of the proteome of thousands of cells from patients or derived model systems at single-cell resolution will allow to more accurately follow the phenotypic trajectory of diseased cells and to better understand, diagnose and treat diseases.



Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III

Thiffault I, Wolf NI, Forget D, Guerrero K, Tran LT, Choquet K, Lavallée-Adam M, Poitras C, Brais B, Yoon G, Sztriha L, Webster RI, Timmann D, van de Warrenburg BP, Seeger J, Zimmermann A, Máté A, Goizet C, Fung E, van der Knaap MS, Fribourg S, Vanderver A, Simons C, Taft RJ, Yates JR 3rd, Coulombe B, Bernard G.

Nat Commun. 2015 Jul 7;6:7623. doi: 10.1038/ncomms8623.

How do our cells build their protein interactome?

Coulombe B, Cloutier P, Gauthier MS.

Nat Commun. 2018 Jul 27;9(1):2955. doi: 10.1038/s41467-018-05448-2.

De novo variants in POLR3B cause ataxia, spasticity, and demyelinating neuropathy

Djordjevic D, Pinard M, Gauthier MS, Smith-Hicks C, Hoffman TL, Wolf NI, Oegema R, van Binsbergen E, Baskin B, Bernard G, Fribourg S, Coulombe B, Yoon G.

Am J Hum Genet. 2021 Jan 7;108(1):186-193. doi: 10.1016/j.ajhg.2020.12.002.




Dr. Benoit Coulombe




Dr. Maxime Pinard

Senior Associate Researcher


Asmae Moursli

PhD Student

Golden Marble

Vijaya Madoo

Administrative Assistant


Dr. Marie-Soleil Gauthier

Senior Associate Researcher


Dr. Esen Sokullu

Post Doctoral Fellow


Christian Poitras

System Analyst


L’Institut de recherches cliniques de Montréal n’est pas responsable du contenu de ce site Web.

The Montreal Clinical Research Institute is not responsible for the content of this website.